About this trial
This study builds on the knowledge that fasting provides metabolic health benefits and that prebiotic interventions can enhance the gut microbiome's metabolic output to likewise improve host health. Whether long-term fasting and dietary fibre interventions could be combined to achieve synergistic improvements in host metabolic health is however unknown. The goal is to provide a proof of concept in a human trial that supplementing 10±4 days fasting with dietary fibre synergistically improves metabolic outcomes via gut microbiome-mediated effects. To assess this, we aim to analyse gut microbiome changes, functional outputs, and key metabolic markers such as butyrate production, glycaemic control and ketosis.
The randomised controlled trial includes 75 participants and has two arms: one involving fasting with fibre supplementation (n = 50) and one involving fasting without fibre supplementation (n = 25). All participants will undergo a fasting period of 10±4 days according to the Buchinger Wilhelmi protocol, followed by a stepwise reintroduction of food of up to 4 days. As dietary fibre we will use maize-derived resistant starch type IV, selected based on its ability to stimulate beneficial gut microbes like Oscillibacter and corn starch as placebo. Two main visits will be conducted: before and at the end of the fasting period. During these visits, blood and stool samples will be collected, and questionnaires will be completed. Additionally, daily measurements of anthropometric parameters and well-being will be recorded. Stool samples will also be collected one month afterwards as a follow-up. Participants' metabolic health will be evaluated through various clinical parameters (e.g., body measurements, blood pressure, glycaemic control, ketones, well-being). Additionally, multi-omics data, including metagenomics and metabolomics, will provide insight into the composition of the microbiome, as well as its outputs and functions. Furthermore, the effects of fasting on extracellular vesicles in blood will be explored.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Men and women
Age: 18-65 years old
Fasting for 10±4 days at the Buchinger Wilhelmi clinic in Überlingen
BMI ≥ 25 kg/m²
Disqualifiers
intake of antibiotics up to 2 months prior the study
regular intake of pre-, post- and probiotics up to 2 months prior the study
diagnosed Crohn's disease, Ulcerative colitis, IBD, coeliac disease
medicated high blood pressure
Trial design
Parallel
Treatments tested in this trial
Fibre Arm
Dietary supplement10±4 days of fasting according to the Buchinger Wilhelmi fasting protocol, followed by a structured food reintroduction period, combined with 20 g/day of maize-derived resistant starch type IV.
Control Arm
Dietary supplement10±4 days of fasting according to the Buchinger Wilhelmi fasting protocol, followed by a structured food reintroduction period, combined with 1.2 g/day of corn starch placebo.
Treatment groups
Trial outcomes
Primary outcomes
Abundance of butyrate-producing gut bacteria
Change in the relative abundance of butyrate-producing gut bacteria assessed by metagenomic profiling of faecal samples.
Change in fasting venous plasma glucose
Fasting venous plasma glucose concentration measured by clinical laboratory analysis (mmol/L).
Secondary outcomes
Change in body weight
Body weight (kg) measured as part of the clinical health assessment.
Change in body mass index
Body mass index calculated from measured body weight and height (kg/m²).
Change in waist circumference
Waist circumference (cm) measured as part of the clinical health assessment.
Change in HbA1c
HbA1c (mmol/mol) measured by clinical laboratory analysis of venous blood.
Other outcomes
Change in the abundance of butyrate-producing gut bacteria
Exploratory assessment of the change in the abundance of butyrate-producing gut bacteria, derived from metagenomic profiling. Additional unscheduled samples may be collected during fasting if spontaneous bowel movements occur.
Change in body weight
Exploratory assessment of change in body weight (kg)
Change in body mass index
Exploratory assessment of change in body mass index (kg/m²).
Change in glycaemic control assessed by continuous glucose monitoring
Exploratory assessment of change in glycaemic control during the post-fasting follow-up period, assessed by open-label continuous glucose monitoring.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Buchinger Wilhelmi Development & Holding GmbH
Lead sponsor
King's College London, Faculty of Life Sciences & Medicine, Department of Nutritional Sciences, London, United Kingdom
Collaborator
Leiden University Medical Center, Department Leiden University Center for Infectious Diseases, 2333ZA, Leiden, Netherlands
Collaborator
TNO, Department Microbiology & Systems Biology, 2333 BE Leiden, Netherlands
Collaborator
Università degli Studi di Milano, Department of Pharmacological and Biomolecular Sciences Rodolfo Paoletti, Milan, Italy
Collaborator
Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Collaborator